glimepiride has been researched along with Alloxan Diabetes in 41 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Time-dependent effects of alpha-lipoic acid/nifedipine/glimepiride combination on diabetic neuropathies were investigated in rats." | 8.12 | Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats. ( Anafi, SB; Bisalla, M; Olurishe, TO; Oraebosi, MI, 2022) |
| " Fasiglifam/TAK-875, a selective GPR40 agonist, enhances glucose-stimulated insulin secretion and improves hyperglycemia." | 7.83 | Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas. ( Ito, R; Matsuda, K; Miyawaki, K; Suzuki, M; Takeuchi, K; Tsujihata, Y, 2016) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 5.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| "Time-dependent effects of alpha-lipoic acid/nifedipine/glimepiride combination on diabetic neuropathies were investigated in rats." | 4.12 | Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats. ( Anafi, SB; Bisalla, M; Olurishe, TO; Oraebosi, MI, 2022) |
| " Fasiglifam/TAK-875, a selective GPR40 agonist, enhances glucose-stimulated insulin secretion and improves hyperglycemia." | 3.83 | Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas. ( Ito, R; Matsuda, K; Miyawaki, K; Suzuki, M; Takeuchi, K; Tsujihata, Y, 2016) |
| "Ginsenoside Rg3 may inhibit the activity of cytochrome P450 enzymes in vitro." | 1.62 | Metabolic study of ginsenoside Rg3 and glimepiride in type 2 diabetic rats by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry. ( Dai, Y; Fu, Y; Li, X; Tao, X; Yang, D; Yu, J; Yue, H; Zheng, F, 2021) |
| "This study was designed to investigate the potency of niosomes, for glimepiride (GLM) encapsulation, aiming at enhancing its oral bioavailability and hypoglycemic efficacy." | 1.46 | Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation. ( AbouSamra, MM; ElShebiney, SA; Mohsen, AM, 2017) |
| "Obesity is a major cause of type 2 diabetes mellitus (T2DM) in mammals." | 1.46 | Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus. ( Nishimura, N; Shimada, Y; Zang, L, 2017) |
| "Diabetic nephropathy was induced by a single dose of streptozotocin (STZ) (60 mg/kg, i." | 1.43 | Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats. ( Chandewar, AV; Mazumder, PM; Tripathi, AS, 2016) |
| " In present investigation, pharmacodynamics and pharmacokinetic interactions with oral hypoglycemic drug, glimepiride (GLM) was studied in streptozotocin (STZ) induced diabetic rats." | 1.43 | Effects of Gymnema sylvestre extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats. ( Duraiswamy, B; Gupta, A; Jadhav, A; Janrao, S; Kamble, B; Khatal, L; Moothedath, I, 2016) |
| "Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition." | 1.40 | Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches. ( Bhatia, M; Bhinchar, MK; Chauhan, DS; Chordia, N; Jatwa, R; Kumar, A; Manivannan, E; Parmar, HS; Raval, I, 2014) |
| "001) increase in the bioavailability of GLIM in the presence of SIL in DN after the 1(st) dose of administration of the drug as compared to GLIM treated rat, whereas at the end of 6(th) week of drug administration, there were significant (p<0." | 1.40 | Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy. ( Chandewar, AV; Mazumder, PM; Tripathi, AS, 2014) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 1.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| " In normal and streptozotocin induced diabetic rats the combination of glimepiride with piperine increased all the pharmacokinetic parameters, such as Cmax, AUC0-n, AUCtotal, t1/2, and MRT, and decreased the clearance, Vd, markedly as compared with the control group." | 1.38 | Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats. ( Rani, TS; Sujatha, S; Veeresham, C, 2012) |
| "The animal models of type 2 diabetes are very complex and are as heterogeneous as the disease." | 1.35 | Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. ( Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A, 2008) |
| "Glimepiride (Gmp) is a third generation antidiabetic sulphonylurea known to possess the antioxidant effect in streptozotocin (STZ) induced diabetes." | 1.35 | Inhibitory effect of glimepiride on nicotinamide-streptozotocin induced nuclear damages and sperm abnormality in diabetic Wistar rats. ( Devi, K; Khanam, S; Rabbani, SI, 2009) |
| " foenum-graecum seed when it was administered orally at high dose level (3 g/kg body weight), which is higher than effective antihyperglycemic dose, and closely observed for 24 hrs for any mortality and next 10 days for any delayed toxic effects on gross behavioral activities." | 1.35 | Antihyperglycemic effect of Trigonella foenum-graecum (fenugreek) seed extract in alloxan-induced diabetic rats and its use in diabetes mellitus: a brief qualitative phytochemical and acute toxicity test on the extract. ( Ahmed, K; Alauddin, M; Mowla, A; Rahman, MA, 2009) |
| "Glimepiride is an oral sulfonylurea drug; nicotinamide is an inhibitor of poly (ADP-ribose) synthetase and a precursor of NAD." | 1.29 | The effects of nicotinamide and glimepiride on diabetes prevention in BB rats. ( Chan, EK; Charles, MA; Cheta, D; Pan, J; Schranz, V, 1995) |
| "Glimepiride is a new sulfonylurea." | 1.29 | Cardiovascular effects of conventional sulfonylureas and glimepiride. ( Geisen, K; Krause, E; Papp, JG; Végh, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 9 (21.95) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 6 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, MK | 1 |
| Eissa, IH | 1 |
| Alesawy, MS | 1 |
| Metwaly, AM | 1 |
| Radwan, MM | 1 |
| ElSohly, MA | 1 |
| Oraebosi, MI | 2 |
| Olurishe, TO | 2 |
| Anafi, SB | 2 |
| Bisalla, M | 2 |
| Gaber, DA | 1 |
| Alhuwaymili, AS | 1 |
| Alhawas, HS | 1 |
| Almutiri, AA | 1 |
| Alsubaiyel, AM | 1 |
| Abdoun, SA | 1 |
| Almutairi, RA | 1 |
| Park, H | 1 |
| Jin Seo, H | 1 |
| Hong, SH | 1 |
| Ha, ES | 1 |
| Lee, S | 1 |
| Kim, JS | 1 |
| Baek, IH | 1 |
| Kim, MS | 1 |
| Hwang, SJ | 1 |
| Abdel-Latif, RG | 1 |
| Ahmed, AF | 1 |
| Heeba, GH | 1 |
| Yang, D | 1 |
| Li, X | 1 |
| Fu, Y | 1 |
| Tao, X | 1 |
| Zheng, F | 1 |
| Yu, J | 1 |
| Yue, H | 1 |
| Dai, Y | 1 |
| Mohsen, AM | 1 |
| AbouSamra, MM | 1 |
| ElShebiney, SA | 1 |
| Zang, L | 1 |
| Shimada, Y | 1 |
| Nishimura, N | 1 |
| Ahmed, OAA | 1 |
| El-Say, KM | 1 |
| Alahdal, AM | 1 |
| Zhou, X | 1 |
| Zhang, R | 1 |
| Zou, Z | 1 |
| Shen, X | 1 |
| Xie, T | 1 |
| Xu, C | 1 |
| Dong, J | 1 |
| Liao, L | 1 |
| Niedowicz, DM | 1 |
| Özcan, S | 1 |
| Nelson, PT | 1 |
| Shannon, RP | 1 |
| Parmar, HS | 1 |
| Bhinchar, MK | 1 |
| Bhatia, M | 1 |
| Chordia, N | 1 |
| Raval, I | 1 |
| Chauhan, DS | 1 |
| Manivannan, E | 1 |
| Jatwa, R | 1 |
| Kumar, A | 1 |
| Ogata, H | 1 |
| Seino, Y | 1 |
| Harada, N | 1 |
| Iida, A | 1 |
| Suzuki, K | 1 |
| Izumoto, T | 1 |
| Ishikawa, K | 1 |
| Uenishi, E | 1 |
| Ozaki, N | 1 |
| Hayashi, Y | 1 |
| Miki, T | 1 |
| Inagaki, N | 1 |
| Tsunekawa, S | 1 |
| Hamada, Y | 1 |
| Seino, S | 1 |
| Oiso, Y | 1 |
| Tripathi, AS | 2 |
| Mazumder, PM | 2 |
| Chandewar, AV | 2 |
| Mohamed, MS | 1 |
| Ali, SA | 1 |
| Abdelaziz, DH | 1 |
| Fathallah, SS | 1 |
| Reginald-Opara, JN | 1 |
| Attama, A | 1 |
| Ofokansi, K | 1 |
| Umeyor, C | 1 |
| Kenechukwu, F | 1 |
| Kamble, B | 1 |
| Gupta, A | 1 |
| Moothedath, I | 1 |
| Khatal, L | 1 |
| Janrao, S | 1 |
| Jadhav, A | 1 |
| Duraiswamy, B | 1 |
| Ito, R | 1 |
| Tsujihata, Y | 1 |
| Suzuki, M | 1 |
| Miyawaki, K | 1 |
| Matsuda, K | 1 |
| Takeuchi, K | 1 |
| Dong, Y | 1 |
| Chen, YT | 1 |
| Yang, YX | 1 |
| Shou, D | 1 |
| Li, CY | 1 |
| Arulmozhi, DK | 1 |
| Kurian, R | 1 |
| Bodhankar, SL | 1 |
| Veeranjaneyulu, A | 1 |
| Hsu, YJ | 1 |
| Lee, TH | 1 |
| Chang, CL | 1 |
| Huang, YT | 1 |
| Yang, WC | 1 |
| Gropler, RJ | 1 |
| Rabbani, SI | 1 |
| Devi, K | 1 |
| Khanam, S | 1 |
| Mowla, A | 1 |
| Alauddin, M | 1 |
| Rahman, MA | 1 |
| Ahmed, K | 1 |
| Wójcicka, G | 1 |
| Jamroz-Wiśniewska, A | 1 |
| Marciniak, A | 1 |
| Łowicka, E | 1 |
| Bełtowski, J | 1 |
| Phadatare, PD | 1 |
| Chandrashekhar, VM | 1 |
| Ahmed, D | 1 |
| Sharma, M | 1 |
| Pillai, KK | 2 |
| Mwafy, SN | 1 |
| Yassin, MM | 1 |
| Yadav, SK | 1 |
| Mishra, S | 1 |
| Mishra, B | 1 |
| Veeresham, C | 1 |
| Sujatha, S | 1 |
| Rani, TS | 1 |
| Darsalia, V | 1 |
| Ortsäter, H | 1 |
| Olverling, A | 1 |
| Darlöf, E | 1 |
| Wolbert, P | 1 |
| Nyström, T | 1 |
| Klein, T | 1 |
| Sjöholm, Å | 1 |
| Patrone, C | 1 |
| Pósa, I | 1 |
| Kocsis, E | 1 |
| Nieszner, E | 1 |
| Pogátsa, G | 1 |
| Koltai, MZ | 1 |
| Mori, Y | 1 |
| Komiya, H | 1 |
| Kurokawa, N | 1 |
| Tajima, N | 1 |
| Khanam, R | 1 |
| Cabrera, W | 1 |
| Genta, S | 1 |
| Said, A | 1 |
| Farag, A | 1 |
| Rashed, K | 1 |
| Sánchez, S | 1 |
| Pan, J | 1 |
| Chan, EK | 1 |
| Cheta, D | 1 |
| Schranz, V | 1 |
| Charles, MA | 1 |
| Takada, Y | 1 |
| Takata, Y | 1 |
| Iwanishi, M | 1 |
| Imamura, T | 1 |
| Sawa, T | 1 |
| Morioka, H | 1 |
| Ishihara, H | 1 |
| Ishiki, M | 1 |
| Usui, I | 1 |
| Temaru, R | 1 |
| Urakaze, M | 1 |
| Satoh, Y | 1 |
| Inami, T | 1 |
| Tsuda, S | 1 |
| Kobayashi, M | 1 |
| Geisen, K | 1 |
| Végh, A | 1 |
| Krause, E | 1 |
| Papp, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097] | 22,119 participants (Anticipated) | Observational | 2023-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
41 other studies available for glimepiride and Alloxan Diabetes
| Article | Year |
|---|---|
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
Topics: Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Humans; Hypogly | 2017 |
Diurnal efficacy of alpha-lipoic acid/nifedipine/glimepiride combination mitigates diabetic neuropathies in rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Nifedipine; Rats; Sul | 2022 |
Synthesized nano particles of glimepiride via spray freezing into cryogenic liquid: characterization, antidiabetic activity, and bioavailability.
Topics: Animals; Area Under Curve; Blood Glucose; Diabetes Mellitus, Experimental; Drug Carriers; Drug Liber | 2022 |
Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
Topics: Administration, Oral; Animals; Arginine; Blood Glucose; Calorimetry, Differential Scanning; Chemistr | 2020 |
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
Topics: Animals; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, Hi | 2020 |
Chronopharmacology of the alpha-lipoic acid/nifedipine/glimepiride combination in the amelioration of retinopathy in rats.
Topics: Animals; Antioxidants; Circadian Rhythm; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Nife | 2021 |
Metabolic study of ginsenoside Rg3 and glimepiride in type 2 diabetic rats by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry.
Topics: Animals; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental | 2021 |
Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Diabetes Mellitus, Experimental; Hypoglycemi | 2017 |
Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus.
Topics: Animals; Animals, Genetically Modified; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel | 2017 |
A PLGA-reinforced PEG in situ gel formulation for improved sustainability of hypoglycaemic activity of glimepiride in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Carriers; Drug Compounding; Drug Delivery Systems; Dr | 2017 |
Hypoglycaemic effects of glimepiride in sulfonylurea receptor 1 deficient rat.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Rats; Sulfonylurea Com | 2019 |
Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gluconeogenes | 2018 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; L | 2013 |
Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches.
Topics: Animals; Computer Simulation; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Pe | 2014 |
KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state.
Topics: Animals; Diabetes Mellitus, Experimental; Diazoxide; Gastric Inhibitory Polypeptide; Glucose; KATP C | 2014 |
Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Interactions; Hypoglycemic Ag | 2014 |
Synthesis and evaluation of novel pyrroles and pyrrolopyrimidines as anti-hyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Hyperglycemia; Hypoglycemic Agents; Magnetic | 2014 |
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Function Tests; Male; Phosp | 2016 |
Molecular interaction between glimepiride and Soluplus®-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Interactions; Female; Hypoglycemic Agents; Male; Poly | 2015 |
Effects of Gymnema sylvestre extract on the pharmacokinetics and pharmacodynamics of glimepiride in streptozotocin induced diabetic rats.
Topics: Alkaloids; Animals; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Gymnema s | 2016 |
Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
Topics: Animals; Benzofurans; Blood Glucose; Diabetes Mellitus, Experimental; Drug Synergism; Glucose Tolera | 2016 |
Urinary Metabolomic Profiling in Zucker Diabetic Fatty Rats with Type 2 Diabetes Mellitus Treated with Glimepiride, Metformin, and Their Combination.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Meta | 2016 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fe | 2008 |
Anti-hyperglycemic effects and mechanism of Bidens pilosa water extract.
Topics: Animals; Bidens; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drugs, Chinese Herbal; | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Inhibitory effect of glimepiride on nicotinamide-streptozotocin induced nuclear damages and sperm abnormality in diabetic Wistar rats.
Topics: Animals; Cell Nucleus; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Niacinamide; Rats | 2009 |
Antihyperglycemic effect of Trigonella foenum-graecum (fenugreek) seed extract in alloxan-induced diabetic rats and its use in diabetes mellitus: a brief qualitative phytochemical and acute toxicity test on the extract.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Do | 2009 |
The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antioxidants; Aryldialkylphosphatase; Diabe | 2010 |
Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Evaluation, Prec | 2011 |
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Melli | 2012 |
Antidiabetic activity evaluation of glimepiride and Nerium oleander extract on insulin, glucose levels and some liver enzymes activities in experimental diabetic rat model.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Blood Glucose; Dia | 2011 |
Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.
Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2012 |
Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats.
Topics: Alanine Transaminase; Alkaloids; Animals; Antioxidants; Area Under Curve; Aspartate Aminotransferase | 2012 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglyc | 2013 |
Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts.
Topics: Animals; Blood Glucose; Blood Pressure; Coronary Circulation; Diabetes Mellitus, Experimental; Dogs; | 2002 |
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2004 |
Involvement of potassium channels in hypoglycemic effect of sertraline.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Hyperglycemia; | 2006 |
Hypoglycemic activity of Ailanthus excelsa leaves in normal and streptozotocin-induced diabetic rats.
Topics: Ailanthus; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin; Ma | 2008 |
The effects of nicotinamide and glimepiride on diabetes prevention in BB rats.
Topics: Administration, Oral; Age Factors; Animals; Body Weight; Diabetes Mellitus, Experimental; Hypoglycem | 1995 |
Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse.
Topics: Animals; Diabetes Mellitus, Experimental; Diglycerides; Gliclazide; Hypoglycemic Agents; Insulin; Ma | 1996 |
Cardiovascular effects of conventional sulfonylureas and glimepiride.
Topics: Animals; Blood Pressure; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; D | 1996 |